Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost--benefit analysis

J Pharm Sci. 1979 Mar;68(3):267-72. doi: 10.1002/jps.2600680304.


Services provided by a clinical pharmacokinetics laboratory were evaluated in terms of an accepted cost--benefit model, and a model to evaluate clinical services provided by the pharmacist is presented. A retrospective study was conducted to evaluate the impact, in terms of patient outcomes, of individualizing gentamicin dosage regimens in severely burned patients. Analysis was conducted using multivariate statistical techniques and appropriate nonparametric and parametric tests to determine significant differences. This analysis provided the necessary data to quantify the impact of the pharmacokinetic service. The findings suggest that significant differences do exist in comparing individually dosed patients against those who were not, based upon discriminant and multiple regression analyses and/or nonparametric tests. Furthermore, the results will be useful for insurance companies, third-party payers, and government agencies in deciding which innovative clinical services should be reimbursed.

MeSH terms

  • Burns / complications*
  • Cost-Benefit Analysis
  • Drug Administration Schedule / economics
  • Gentamicins / administration & dosage*
  • Gentamicins / adverse effects
  • Gentamicins / therapeutic use
  • Humans
  • Kinetics
  • Length of Stay / economics
  • Models, Theoretical
  • Pharmaceutical Services / economics
  • Sepsis / complications
  • Sepsis / drug therapy*
  • Sepsis / mortality


  • Gentamicins